Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 17, 2019 Filed Jul 19, 2019 21:24 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 1,000 | $5.64 | $5,640.00 |
DisclosureSEC source: 0001209191-19-042799 · doc4.xml · nonDerivative · entry 5 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,102 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.97 to $5.63, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F7 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.65 to $5.63, inclusive. Read SEC document |
| July 17, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.85 | $351.00 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 24 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,998 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 17, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.84 | $379.60 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 24 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,487 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 17, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.85 | $351.00 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 24 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,763,922 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 16, 2019 Filed Jul 19, 2019 21:24 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 478 | $5.76 | $2,753.28 |
DisclosureSEC source: 0001209191-19-042799 · doc4.xml · nonDerivative · entry 4 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,102 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.97 to $5.63, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F6 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.79 to $5.71, inclusive. Read SEC document |
| July 16, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.88 | $352.80 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 23 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,938 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 16, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.87 | $381.55 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 23 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,422 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 16, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.88 | $352.80 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 23 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,763,862 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 16, 2019 Filed Oct 25, 2019 21:15 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 75 | $5.76 | $432.00 |
DisclosureSEC source: 0001209191-19-054168 · doc4.xml · nonDerivative · entry 2 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,704 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 15, 2019 Filed Jul 19, 2019 21:24 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 2,200 | $5.69 | $12,518.00 |
DisclosureSEC source: 0001209191-19-042799 · doc4.xml · nonDerivative · entry 3 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,580 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.97 to $5.63, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F5 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.77 to $5.67, inclusive. Read SEC document |
| July 15, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.85 | $351.00 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 22 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,878 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 15, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.84 | $379.60 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 22 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,357 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 15, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.85 | $351.00 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 22 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,763,802 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 12, 2019 Filed Jul 19, 2019 21:24 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 2,893 | $5.89 | $17,039.77 |
DisclosureSEC source: 0001209191-19-042799 · doc4.xml · nonDerivative · entry 2 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,780 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.97 to $5.63, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F4 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.97 to $5.80, inclusive. Read SEC document |
| July 12, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.01 | $360.60 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 21 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,818 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 12, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.01 | $390.65 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 21 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,292 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 12, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.01 | $360.60 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 21 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,763,742 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 11, 2019 Filed Jul 19, 2019 21:24 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 900 | $5.74 | $5,166.00 |
DisclosureSEC source: 0001209191-19-042799 · doc4.xml · nonDerivative · entry 1 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,673 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.97 to $5.63, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F3 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.75 to $5.70, inclusive. Read SEC document |
| July 11, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $5.93 | $355.80 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 20 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,758 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 11, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $5.93 | $385.45 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 20 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,227 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 11, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $5.93 | $355.80 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 20 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,763,682 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 11, 2019 Filed Oct 25, 2019 21:15 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 75 | $5.83 | $437.25 |
DisclosureSEC source: 0001209191-19-054168 · doc4.xml · nonDerivative · entry 1 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,629 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 21:16 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 2,300 | $5.90 | $13,570.00 |
DisclosureSEC source: 0001209191-19-041961 · doc4.xml · nonDerivative · entry 9 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,573 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.42 to $5.81, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F10 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.97 to $5.81, inclusive. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 21:17 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 50 | $5.97 | $298.50 |
DisclosureSEC source: 0001209191-19-041963 · doc4.xml · nonDerivative · entry 30 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,554 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 10, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.07 | $364.20 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 19 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,698 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 10, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.06 | $393.90 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 19 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,162 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 10, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.07 | $364.20 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 19 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,763,622 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 09, 2019 Filed Jul 12, 2019 21:16 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 500 | $6.11 | $3,055.00 |
DisclosureSEC source: 0001209191-19-041961 · doc4.xml · nonDerivative · entry 8 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,873 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.42 to $5.81, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F9 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.14 to $6.05, inclusive. Read SEC document |
| July 09, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.15 | $369.00 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 18 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,638 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 09, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.14 | $399.10 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 18 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,097 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 09, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.15 | $369.00 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 18 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,763,562 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 08, 2019 Filed Jul 12, 2019 21:16 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 400 | $6.25 | $2,500.00 |
DisclosureSEC source: 0001209191-19-041961 · doc4.xml · nonDerivative · entry 7 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,373 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.42 to $5.81, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F8 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.32 to $6.20, inclusive. Read SEC document |
| July 08, 2019 Filed Jul 12, 2019 21:17 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 50 | $6.27 | $313.50 |
DisclosureSEC source: 0001209191-19-041963 · doc4.xml · nonDerivative · entry 29 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,504 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 08, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.37 | $382.20 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 17 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,578 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 08, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.36 | $413.40 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 17 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,032 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 08, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.37 | $382.20 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 17 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,763,502 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 05, 2019 Filed Jul 12, 2019 21:16 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 668 | $6.31 | $4,215.08 |
DisclosureSEC source: 0001209191-19-041961 · doc4.xml · nonDerivative · entry 6 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,773 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.42 to $5.81, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F7 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.39 to $6.30, inclusive. Read SEC document |
| July 05, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.49 | $389.40 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 16 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,518 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 05, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.48 | $421.20 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 16 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,967 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 05, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.49 | $389.40 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 16 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,763,442 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 03, 2019 Filed Jul 12, 2019 21:16 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 729 | $6.32 | $4,607.28 |
DisclosureSEC source: 0001209191-19-041961 · doc4.xml · nonDerivative · entry 5 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,441 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.42 to $5.81, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F6 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.35 to $6.28, inclusive. Read SEC document |
| July 03, 2019 Filed Jul 12, 2019 21:17 UTC |
Young CarolineDirector
|
PurchaseCommon Stock | 50 | $6.36 | $318.00 |
DisclosureSEC source: 0001209191-19-041963 · doc4.xml · nonDerivative · entry 28 Young Caroline · CIK 0001684087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,454 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 03, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.46 | $387.60 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 15 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,458 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 03, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.45 | $419.25 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 15 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,902 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 03, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.46 | $387.60 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 15 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,763,382 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 02, 2019 Filed Jul 12, 2019 21:16 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 2,802 | $6.36 | $17,820.72 |
DisclosureSEC source: 0001209191-19-041961 · doc4.xml · nonDerivative · entry 4 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,170 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.42 to $5.81, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F5 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.40 to $6.35, inclusive. Read SEC document |
| July 02, 2019 Filed Jul 26, 2019 21:26 UTC |
Galante Joseph CDirector
|
PurchaseCommon Stock | 60 | $6.49 | $389.40 |
DisclosureSEC source: 0001209191-19-043395 · doc4.xml · nonDerivative · entry 14 Galante Joseph C · CIK 0001632384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,398 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 02, 2019 Filed Jul 26, 2019 21:28 UTC |
Krogulski KennethDirector
|
PurchaseCommon Stock | 65 | $6.49 | $421.85 |
DisclosureSEC source: 0001209191-19-043398 · doc4.xml · nonDerivative · entry 14 Krogulski Kenneth · CIK 0001695580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,837 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 02, 2019 Filed Jul 26, 2019 21:27 UTC |
KAZIMI A JDirector · Chairman and CEO · 10% owner
|
PurchaseCommon Stock | 60 | $6.49 | $389.40 |
DisclosureSEC source: 0001209191-19-043397 · doc4.xml · nonDerivative · entry 14 KAZIMI A J · CIK 0001075050 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,763,322 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. Read SEC document |
| July 01, 2019 Filed Jul 12, 2019 21:16 UTC |
Bernard Gordon RDirector
|
SaleCommon Stock | 2,788 | $6.41 | $17,871.08 |
DisclosureSEC source: 0001209191-19-041961 · doc4.xml · nonDerivative · entry 3 Bernard Gordon R · CIK 0001470015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,972 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.42 to $5.81, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F4 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.42 to $6.38, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.